Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus.
Level 5 - mechanism / opinion, no new human data
Preclinical structural biology and animal research (mice and non-human primates) with no human clinical data.
PubMed 24179220 · doi:10.1126/science.1243283
What was done
Researchers used structure-based design to engineer variants of the respiratory syncytial virus (RSV) fusion (F) glycoprotein locked in its prefusion conformation to preserve antigenic site Ø against extremes of pH, osmolality, and temperature. Structural stabilization mechanisms (engineered cysteine mutations and cavity-filling modifications) were characterized through six crystal structures, and immunogenicity was tested via immunization in mice and macaques.
What was found
Engineered prefusion RSV F variants successfully maintained antigenic site Ø integrity under stress. In both mice and macaques, immunization with site Ø-stabilized variants elicited RSV-specific neutralizing antibody titers reported as many times higher than the protective threshold. The abstract provides no specific quantitative titers, animal counts, or confidence intervals.
Why it matters
This study provided the foundational structural blueprint for stabilizing RSV prefusion F glycoprotein, establishing the basis for successful modern RSV vaccine development.
Limits
The study is entirely preclinical, relying on structural assays and animal models (mice and macaques) without human data. Exact sample sizes, precise quantitative antibody levels, and in vivo protection against live virus challenge are not reported in the abstract.
Cited by
- supports Structural biologist Dr. Jason McLellan engineered two-proline mutations to lock viral surface proteins into the pre-fusion conformation initially for Respiratory Syncytial Virus (RSV) and subsequently for MERS-CoV.